CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

76018

BIOEQUIVALENCY REVIEW(S)

8

OFFICE OF GENERIC DRUGS
DIVISION OF BIOEQUIVALENCE

ANDA #: 76-018 SPONSOR: Bedford Lab.

DRUG AND DOSAGE FORM: Amiodarone HCl Injection

STRENGTH(S): 50 mg/ml, 3 ml vials

TYPES OF STUDIES: waiver

CLINICAL STUDY SITE(S): N/A

ANALYTICAL SITE(S): N/A

STUDY SUMMARY: Please see review

DISSOLUTION: N/A

DSI INSPECTION STATUS

Inspection needed: YES / (NO)	Inspection status:	Inspection results:
First Generic NO	Inspection requested: (date)	
New facility ____	Inspection completed: (date)	
For cause ____		
other ____		

PRIMARY REVIEWER: (NAME) BRANCH:

INITIAL: /S/ DATE: 1/23/01

TEAM LEADER: (NAME) BRANCH:

INITIAL: /S/ DATE: 1/23/2001

DIRECTOR, DIVISION OF BIOEQUIVALENCE: DALE P. CONNER, Pharm. D.

INITIAL: DPC DATE: 1/25/01

BIOEQUIVALENCY COMMENTS TO BE PROVIDED TO THE APPLICANT

ANDA: 76-018 APPLICANT: Bedford Laboratories™

DRUG PRODUCT: Amiodarone HCl Injection 50 mg/mL, 3 mL vials

The Division of Bioequivalence has completed its review and has no further questions at this time.

Please note that the bioequivalency comments provided in this communication are preliminary. These comments are subject to revision after review of the entire application, upon consideration of the chemistry, manufacturing and controls, microbiology, labeling, or other scientific or regulatory issues. Please be advised that these reviews may result in the need for additional bioequivalency information and/or studies, or may result in a conclusion that the proposed formulation is not approvable.

Sincerely yours,

/S/

Dale P. Conner, Pharm. D.
Director, Division of Bioequivalence
Office of Generic Drugs
Center for Drug Evaluation and Research

CC: ANDA 76-018
ANDA DUPLICATE
DIVISION FILE
HFD-651/ Bio Drug File
HFD-650/ Reviewer

Printed in final on / /

Endorsements: (Final with Dates)
HFD-652/ S. Pradhan SP.
HFD-650/ Y. Huang YH 1/23/2001
HFD-617/ K. Scardina
HFD-650/ D. Conner DC 1/25/01

BIOEQUIVALENCY - ACCEPTABLE

Submission Date: October 27, 2000

1. **WAIVER** (WAI) oic

Strengths: 50 mg/mL, 3 mL vial
Outcome: AC

Outcome Decisions: **AC** - Acceptable

Amiodarone Hydrochloride Injection
50 mg/mL , 3 mL vials
ANDA #76-018
Reviewer: Sikta Pradhan

Bedford Laboratories™
Bedford,Ohio
Submitted:
October 27, 2000

REVIEW OF A WAIVER REQUEST

The sponsor has submitted a request for waiver of *in vivo* bioequivalence study requirements for its test product Amiodarone 50 mg/mL in 3 mL vials for injection.

Table 1. Comparative formulations for the TEST and REFERENCE products

Ingredient	TEST	REFERENCE Cordarone^{R}
Amiodarone HCl	50 mg/mL	50 mg/mL
Polysorbate 80	100 mg/mL	100 mg/mL
Benzyl alcohol	20.2 mg/mL	20.2 mg/mL
Water for Injection	QS to 1 mL	QS to 1 mL

Comments:

1. The formulations for the test product, amiodarone HCl Injection and Cordarone® manufactured by Wyeth Ayerst are identical. The compositions of the test and reference products are given in Table 1.

2. In order to qualify for waiver of *in vivo* bioequivalence study requirements under 21 CFR 320.22(b)(1), the following conditions must be satisfied:

- **The drug product is a parenteral solution intended solely for administration by injection.**

The test product's proposed labeling (Dosage and Administration section) states that "The direct intravenous route of administration is preferred. Intramuscular administration is not recommended".

- **Contains the same active and inactive ingredients in the same concentration as a drug product that is the subject of an approved full NDA**

For both test and reference products, the active ingredient is amiodarone HCl 50 mg/mL. The test product contains the same inactive ingredients in the same concentrations as the reference formulation does.

Recommendation:

The Division of Bioequivalence agrees that the information submitted by Bedford Laboratories™ demonstrates that Amiodarone HCl 50 mg/mL, 3mL vials for injection fall under 21 CFR Section 320.22(b)(1) of the Bioavailability/Bioequivalence Regulations. The waiver of in vivo bioequivalence study requirements for the Amiodarone HCl 50 mg/mL, 3mL vials for injection of the test product is granted. From the Bioequivalence point of view, the Division of Bioequivalence deems the test injectable formulation to be bioequivalent to Cordarone® 50 mg/mL manufactured by Wyeth Ayerst.

/S/ 1/23/01

Sikta Pradhan
Review Branch I
Division of Bioequivalence

RD INITIALED YCHUANG
FT INITIALED YCHUANG /S/ Date 1/23/2001

Concur: /S/ Date 1/25/01
Dale P. Conner, Pharm.D.
Director, Division of Bioequivalence

cc: ANDA 76-018 (original, duplicate), HFD-650(Director), HFD-652 (Huang, Pradhan), Drug File, Division File.